BioSpace News Archive

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York.

Notable Labs, Ltd. announced that it has filed its Quarterly Report on Form 10-Q containing financial results for the third quarter and nine months ended September 30, 2023.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”) today reported financial results for the third quarter ended September 30, 2023, and provided corporate and clinical updates.

Aethlon Medical, Inc. reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2023, and recent updates.

Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”) announced today that it has entered into a definitive agreement to acquire Motion Solutions, a leading provider of highly engineered integrated solutions, for cash consideration of $189 million, subject to customary purchase price adjustments and closing conditions, including applicable regulatory approvals.

Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the first quarter of fiscal 2024 ended September 30, 2023.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.

Inhibikase Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments.